InGel Therapeutics
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
InGel Therapeutics firmographics
Firmographics- Name
- InGel Therapeutics
- Legal name
- InGel Therapeutics
- Website
- https://ingeltx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
InGel Therapeutics industry classification
Industry- Product category
- Cell Therapy for Retinal Diseases
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where InGel Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
InGel Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Cell Therapy Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing novel cell therapies for retinal degenerative diseases. The company is focused on advancing its lead cell therapy product from early discovery through non-human primate toxicology and into first-in-human clinical trials. Revenue will be generated through commercialization of therapeutic products upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
InGel Therapeutics product offering
Product offeringCore offering
InGel Therapeutics develops engineered cell therapies for retinal degenerative diseases, combining high-purity Precursor Cells (rods, cones, retinal ganglion cells) with a biomimetic hyaluronic acid/gelatin hydrogel delivery matrix. Its lead cell-gel therapy has advanced into first-in-human clinical trials for retinitis pigmentosa, dry AMD, and glaucoma, while the Regenesis platform supports neuroprotective target discovery using single-cell proteomics. The company is pre-revenue and focused on clinical development rather than commercial product sales today.
Product overview
InGel Therapeutics is a biotechnology company developing engineered cell therapies for retinal degeneration. The company operates three integrated technology platforms: the Cellular Development Platform for producing high-purity Precursor Cells (rods, cones, and retinal ganglion cells), the Hydrogel Delivery Platform for safe in vivo cell delivery via biomimetic hyaluronic acid/gelatin matrices, and the Regenesis research platform for discovering and validating neuroprotective targets. The lead product is a cell-gel therapy combining precursor cells with the hydrogel delivery system, currently in clinical trials for retinitis pigmentosa, dry age-related macular degeneration, and glaucoma.
Differentiator
Problem solved
Functional benefit
Brands
- Regenesis: A target discovery and validation platform for neuroprotective pathways in the eye. It leverages single cell proteomics profiling for rod photoreceptors and their secretome.
Companies that use InGel Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
InGel Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
InGel Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MIT (Massachusetts Institute of Technology)coreStrategic collaboration with MIT. Dr. Singh leads strategic collaborations with top-tier academic institutions including MIT, Harvard, and CUNY for research and development activities.
- Harvard Medical School / Schepens Eye Research InstitutecoreStrategic collaboration with Harvard Medical School institutions. Co-founder Michael Young is affiliated with Schepens Eye Research Institute, Harvard Medical School. The company has strategic collaborations with Harvard-affiliated researchers.
- CUNY (City University of New York)coreStrategic collaboration with CUNY. Dr. Stephen Redenti is a Professor at Lehman College and in the CUNY Graduate Center, supporting the company's research in cell and tissue communication for neural tissue repair.
- Stanford UniversityminorStanford University is also part of the ARPA-H THEA program research consortium working on eye transplantation alongside InGel Therapeutics and other institutions.
- University of Colorado Anschutz Medical CampusminorUniversity of Colorado Anschutz Medical Campus is also part of the ARPA-H THEA program research consortium working on eye transplantation alongside InGel Therapeutics and other institutions.
- University of Miami Bascom Palmer Eye InstituteminorBascom Palmer Eye Institute is also part of the ARPA-H THEA program research consortium working on eye transplantation alongside InGel Therapeutics and other institutions.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
InGel Therapeutics competitors and assessment
Company assessmentDirect peers
- jCyte: jCyte is a clinical-stage biotech developing a retinal progenitor cell therapy (jCell) for retinitis pigmentosa—the same lead indication as InGel's precursor cell product. It is the most directly comparable competitor in the ophthalmic stem cell space.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell transplant therapies, including OpRegen for geographic atrophy/AMD—a leading retinal cell therapy competitor using a similar transplanted-cell modality for ophthalmic indications overlapping with InGel's pipeline.
Emerging players
- BlueRock Therapeutics: BlueRock (a Bayer subsidiary) develops engineered cell therapies from pluripotent stem cells for diseases of the CNS and other tissues. Its pluripotent stem cell differentiation approach parallels InGel's Precursor Cell platform with high-purity, fate-controlled differentiation as a core design principle.
- REGENXBIO: REGENXBIO is advancing AAV-based gene therapies for retinal diseases (including wet AMD and rare inherited retinopathies). Its subretinal gene therapy delivery strategy competes head-to-head with InGel's subretinal cell + hydrogel injection in the same retinal indications.
- Adverum Biotechnologies: Adverum is advancing gene therapies (e.g., ADVM-022/Ixo-vec) for wet AMD delivered via intravitreal injection, directly competing in the same treated eye disease space and using similar ocular delivery routes to InGel's hydrogel platform.
Broad incumbents
- Spark Therapeutics (Roche): Spark Therapeutics developed and commercialized LUXTURNA, the first FDA-approved gene therapy for an inherited retinal disease (RPE65), establishing the regulatory and clinical paradigm against which any retinal disease-modifying therapy—including InGel's cell therapy—will be benchmarked.
- Astellas Pharma (via acquisition of Universal Cells / OcTx programs): Astellas acquired retinal cell therapy assets and is developing Izervay for geographic atrophy (dry AMD)—one of InGel's stated secondary indications—positioning Astellas as a deep-pocketed incumbent in the dry AMD competitive landscape.
- Apellis Pharmaceuticals: Apellis commercializes SYFOVRE, the first FDA-approved treatment for geographic atrophy (a form of dry AMD)—InGel's secondary indication. SYFOVRE's commercial success validates the dry AMD market and is the standard-of-care benchmark InGel will need to address.
Regional players
- Aldeyra Therapeutics: Aldeyra Therapeutics develops novel therapeutics for ocular and inflammatory diseases; the company acquired Helio Vision, which was co-founded by InGel clinical advisor Dean Eliott. Aldeyra competes for the same retina/ophthalmology commercial channel and clinician mindshare.
- Ocugen: Ocugen is developing both an AAV gene therapy (OCU400) for retinitis pigmentosa and other inherited retinal diseases, putting it in direct clinical-stage competition with InGel's lead cell therapy for the same orphan patient population.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InGel Therapeutics social profiles
Digital presenceInGel Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
InGel Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
InGel Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InGel Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InGel Therapeutics
What does InGel Therapeutics do?
InGel Therapeutics develops engineered cell therapies for retinal degenerative diseases, combining high-purity Precursor Cells (rods, cones, retinal ganglion cells) with a biomimetic hyaluronic acid/gelatin hydrogel delivery matrix. Its lead cell-gel therapy has advanced into first-in-human clinical trials for retinitis pigmentosa, dry AMD, and glaucoma, while the Regenesis platform supports neuroprotective target discovery using single-cell proteomics. The company is pre-revenue and focused on clinical development rather than commercial product sales today.
Is InGel Therapeutics a public or private company?
InGel Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was InGel Therapeutics founded?
InGel Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is InGel Therapeutics based?
InGel Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does InGel Therapeutics make money?
One revenue line is on record: cell Therapy Development and Commercialization.
Who are InGel Therapeutics's main competitors?
Direct peers on record are jCyte and Lineage Cell Therapeutics. Emerging players are BlueRock Therapeutics, REGENXBIO and Adverum Biotechnologies. Broad incumbents are Spark Therapeutics (Roche), Astellas Pharma (via acquisition of Universal Cells / OcTx programs) and Apellis Pharmaceuticals. Regional players are Aldeyra Therapeutics and Ocugen.
Does InGel Therapeutics have an API?
No public API is recorded for InGel Therapeutics.
What industry is InGel Therapeutics in?
InGel Therapeutics's product category is Cell Therapy for Retinal Diseases. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.